TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells

@inproceedings{Tuthill2015TRAILR2specificAA,
  title={TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells},
  author={Mark H Tuthill and Antonella Montinaro and Julia Zinngrebe and Katharina Prieske and Peter Dr{\'a}ber and Stefan Prieske and Tom Newsom-Davis and Silvia von Karstedt and Jonathan D. Graves and Henning Walczak},
  booktitle={Oncogene},
  year={2015}
}
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells while sparing normal tissues. Despite promising preclinical results, few patients responded to treatment with recombinant TRAIL (Apo2L/Dulanermin) or TRAIL-R2-specific antibodies, such as conatumumab (AMG655). It is unknown whether this was due to intrinsic TRAIL resistance within primary human cancers or insufficient agonistic activity of the TRAIL-receptor (TRAIL-R)-targeting drugs. Fc… CONTINUE READING
28 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…